More on Chelsea-Lundbeck deal: Lundbeck gains rights to Northera

By acquiring Chelsea Therapeutics (CHTP), Lundbeck (HLUKF) gains the rights to Chelsea's Northera treatment for neurogenic orthostatic hypotension, a disease that is associated with neurological disorders such as Parkinson's.

Northera recently won FDA approval and is due to be launched later this year.

Lundbeck's offer of $7.94 a share comprises $6.44 a share in cash and up to $1.50 of contingent value rights (CVRs) that will be related to Northera's commercial performance.

The transaction is expected to close in Q3.

Chelsea Therapeutics' shares are +32% at $6.60. (PR)


From other sites
Comments (3)
  • User 24072113
    , contributor
    Comment (1) | Send Message
    Great News!!!
    8 May 2014, 10:00 AM Reply Like
  • berniespear
    , contributor
    Comments (251) | Send Message
    8 May 2014, 02:16 PM Reply Like
  • holydawn
    , contributor
    Comments (145) | Send Message
    any reason to believe short covering will occur above the 6.44 price?
    8 May 2014, 09:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs